# A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

> **NCT07221162** · PHASE1 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 140 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Aluminum Hydroxide Suspension
- **BIOLOGICAL:** Boost-2867
- **BIOLOGICAL:** CpG 7909
- **OTHER:** Sodium Chloride, 0.9%

## Key facts

- **NCT ID:** NCT07221162
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-05
- **Primary completion:** 2026-11-24
- **Final completion:** 2026-11-24
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221162, "A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07221162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*